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Abstract
The movement for a national pharmacare plan in Canada is growing, but at the same time the multinational 
pharmaceutical companies and their supporters are critical of such a move. The three major arguments that 
they make are that all that is needed is to “fill in the gaps,” ie, cover those who currently are uninsured or 
underinsured, that private drug plans are superior to public ones because they cover a larger number of drugs 
and that Canada cannot afford pharmacare. This commentary examines each of these arguments and makes the 
case that none of them is valid and that it is time to get on with implementing pharmacare.
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Two recent articles in the International Journal of Health Policy and Management have separately made the case why Canada should adopt a universal, public 
pharmacare plan. Hajizadeh and Edmonds1 use data from 
six nationally representative surveys of Household Spending 
conducted by Statistics Canada between 2010 and 2015 to 
show how inequitable the coverage is for medicines when 
it comes to out-of-pocket payments. Depending on where 
you live in Canada as few as 1 in 20 households to as many 
as 1 in 10 households are spending 6% of their income on 
prescription drugs. Lewis2 runs through the key players in the 
pharmacare debate – physicians, chain pharmacies, private 
drug insurers, the pharmaceutical industry and the public – 
and discusses how each will advance or impede the movement 
towards pharmacare.
The prospects for pharmacare, a plan that would ensure 
access to all medically necessary drugs for Canadians at 
minimal to no out-of-pocket cost, are better now than they 
have been since the early 1970s.3 The mandate letter from 
Prime Minister Justin Trudeau to his Minister of Health 
calls for her to implement “national universal pharmacare”4 
and the social democratic New Democratic Party, the most 
likely ally of the Liberals in the new minority government, 
has placed pharmacare at the top of its priority list. However, 
the going will not be all smooth. The mandate letter is vague 
about what any future pharmacare plan will look like and the 
provincial and territorial premiers are, at best, lukewarm to 
the idea. Their first priority for the federal government is for 
it to increase its transfers for current healthcare services by 
5.2% annually. After that, they may be willing to consider 
pharmacare if provinces have an opt out clause.5
But even before pharmacare has a chance to be born, the 
knives are out to try and ensure that it never sees the light 
of day. Who is wielding those knives? The answer to that 
question comes from an essay by one of Canada’s pre-eminent 
health economists, Robert Evans. Evans and colleagues6 
remind us that “Every dollar of expenditure is a dollar of 
someone’s income.” The income earners in this case are the 
pharmaceutical companies and to a lesser extent the private 
insurance companies. 
Pharmacare means monopsony buying power for the 
government and the ability to extract large discounts. For 
example, Australia, through its Pharmaceutical Benefits 
Scheme, struck a 5-year deal with pharmaceutical companies 
to supply the country with all of the antiretroviral drugs 
necessary to treat the 230 000 Australians with hepatitis C 
for A$1 billion, thereby lowering the per person treatment 
cost from A$20 000 to about A$4300.7 There is also the 
inevitable reality that not all drugs will be listed on a national 
formulary since only about 1 in 10 new drugs are significantly 
therapeutically superior to already existing medicines.8
So it should not be any surprise that the knives are in 
the hands of the brand-name pharmaceutical industry,9 its 
supporters10-12 and the insurance companies.13 They all agree 
that all Canadians should be covered but they insist that 
national pharmacare is not the way to go. The arguments 
vary somewhat, but typically emphasize three themes: most 
Canadians are insured so we only need to fill in the gaps, 
pharmacare will deprive people of drugs that their private 
insurance is paying for and pharmacare is too costly and we 
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cannot afford it. None of those arguments bears scrutiny. 
About 60% of Canadians are covered by private insurance 
and many of the rest qualify for one of the provincial public 
insurance plans, but that still leaves almost 1 in 10 Canadians 
with cost-related nonadherence, especially those who are 
poor and/or in poor health.14 The province of Quebec tried 
to deal with this problem by requiring any employer who 
offers health benefits to include drugs in those benefits and 
for everyone else the government steps in. On some measures 
such as cost-related nonadherence Quebec does better than 
other provinces but given the poor coverage in other provinces 
that is not the right comparison. The right comparison is with 
countries that provide universal coverage and on that measure 
Quebec lags behind countries such as Australia, Germany, the 
Netherlands and the United Kingdom. Similarly, a greater 
percentage of people in Quebec report spending more than 
$1000 out-of-pocket on drugs and total per capita spending 
on drugs in Quebec ($1087) is substantially higher than 
the average in the rest of Canada ($912) and countries with 
universal coverage ($826).15 Moreover, continuing to heavily 
rely on private insurance means higher administrative costs, 
less generic substitution, annual or lifetime caps on coverage 
for some people and taxpayer subsidies since health benefits 
are provided tax free.16-19
Defenders of the current system make much of the fact 
that private insurance plans cover a greater percent of drugs 
approved by Health Canada than do public provincial plans. 
Citing research by the Canadian Health Policy Institute, the 
Canadian Life and Health Insurance Association makes the 
case that private insurance is superior to public insurance 
because of the 479 new drugs approved by Health Canada 
from 2008 to 2017, 87% were covered by at least one private 
drug plan, compared to 45% that were covered by at least one 
public plan.20 Similarly, a report from Innovative Medicines 
Canada, the lobby group for the multinational drug companies 
operating in Canada, claims that Canada ranked 18th out of 20 
Organisation for Economic Co-operation and Development 
(OECD) countries in terms of the percent of new drugs and 
new drug combinations introduced between January 1, 2010 
and December 31, 2014 that were publicly funded.21 (I made 
three attempts to contact Innovative Medicines Canada to 
obtain the list of drugs that were evaluated in this report but 
never received an answer.)
The rationale behind the notion that the more drugs covered 
the better the plan, is based on work by Frank Lichtenberg who 
claims that more use of newer medicines is associated with 
lower morbidity, mortality and overall healthcare spending.22 
However, Lichtenberg’s conclusions are heavily contested by 
a number of authors.23-26 (Lichtenberg has responded to his 
critics and defended his work.27,28) Nor do more drugs equate 
to more consumer choice, even ignoring that it is doctors 
who actually make the choice. More than half of the new 
drugs and new indications for existing drugs introduced 
onto the French market were rated as “nothing new” by the 
independent French drug bulletin Prescrire International and 
17% were judged to have a negative benefit to harm ratio and 
should never have been approved.29
As of 2013, most private drug plans were not using 
formularies,30 but that situation is changing and in recent 
years two large plans announced the use of formularies.31,32 
If a national formulary for pharmacare is “well-constructed 
by disinterested experts” as Lewis recommends, with a “safety 
valve of a separate pool to cover some experimental, high 
cost” products, then any drugs that are left off are going to be 
ones that “have failed to meet reasonable standards of efficacy 
and/or cost-effectiveness.”2
Nearly all of the opponents of pharmacare talk about the cost 
of such a program. The Canadian Life and Health Insurance 
Association, in its brief to the federally appointed Advisory 
Council on the Implementation of National Pharmacare, said 
that expanding the current private/public system was the best 
way “to minimize the overall fiscal impact to government” 
while increasing coverage.20 As another example, the chief 
economist for the Canadian Chamber of Commerce said, 
“A single-payer plan will likely result in increased deficits 
and taxes, both of which are not in the interest of average 
Canadians.”12 This type of statement draws on the $19.3 billion 
estimated cost for pharmacare from the Parliamentary Budget 
Office.33 But that estimate assumes that the entire cost will be 
borne by the federal government, whereas most advocates 
for pharmacare are talking about a joint federal-provincial/
territorial plan where the cost is shared by different levels of 
government. The Parliamentary Budget Office is also using 
as a model the Quebec formulary which is the most generous 
one in Canada34 and not necessarily the one that will form the 
basis for a national formulary.
What these naysayers want is for Canada to continue with 
its mix of public and private (insurance and out-of-pocket) 
payment that leaves the country with an annual per capita 
drug expenditure of US$806 against an OECD average of 
US$564. Public spending on prescription drugs in Canada 
is near the bottom of the OECD countries. Is it any wonder 
that we spend more per person than nearly all of them.35 
One of the main reasons why other countries can keep their 
spending so much lower than Canada’s is because national 
drug insurance allows for monopsony buying power. How 
do these countries manage to afford national drug insurance 
without bankrupting themselves, is a question that opponents 
never address. 
Drawing on an analogy from Evans and colleagues, the 
ideas of those opposed to pharmacare are like zombies.6 You 
think that you’ve killed them with rational arguments but they 
keep rising from the dead. It is time to deliver the final death 
blow and get on with delivering pharmacare and helping to 
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